Medicare prices get one ceiling for crossover drugs

A drug that can be billed two ways in Medicare would no longer get two separate price ceilings. In Washington, the Centers for Medicare & Medicaid Services, or CMS, says crossover drugs should be priced as one unit when Medicare Part B, the medical benefit, and Part D, the prescription-drug benefit, both apply.

That matters for people who use medicines that move between a doctor’s office and a pharmacy counter, because the ceiling Medicare can negotiate helps shape what gets paid for the drug in both settings. CMS reads section 1194(c)(1)(B) to call for a single amount for each selected drug when both parts apply, rather than one number for the office side and another for the pharmacy side.

Two billing lanes, one ceiling

Under CMS’s reading, the combined amount would capture the Part B payment amount under section 1847A(b)(4) and the Part D-covered amount for the same selected drug. The agency says that ceiling would apply to all dosage forms and strengths of the drug that are payable under Part B and covered under Part D, so the full package stays together even when the billing route changes.

The same approach would carry over to negotiation and renegotiation. CMS says it would still be building one crossover amount, not resetting the math each time the drug comes back through the program.

Why the single figure matters

For beneficiaries, manufacturers, Part D plans, and providers and pharmacies that handle the claims, the combined ceiling is the number that can ripple through the rest of the transaction. It ties together the two Medicare payment streams instead of letting them operate as separate price tracks for the same medicine.

That does not make the drug any less complicated to bill, but it does make CMS’s position clearer: when one selected drug lives in both Medicare parts, the ceiling follows the drug, not the billing channel.